Pricing, Reimbursement, Market Access - Pharmaceutical and Biotech industries
December 2019

Embracing digital technology can better enable processes and prioritize requirements

At the 61st ASH Annual Meeting and Exposition, we will be showcasing how the PRMA digital applications allow our customers more time to focus on crafting their market access strategy by marrying the best consulting experience with cutting-edge digital efficiency.

Meet with us at ASH >>


November 2019

Digital innovation empowers global teams and local affiliates to shorten the time to market access

This market access case study demonstrates how a top-10 global pharmaceutical company quickly realized the benefits of digital transformation in market access.

Read more >>


November 2019

Toby Gosden joins PRMA Consulting

PRMA Consulting is delighted to welcome Toby Gosden to the role of Director at PRMA Consulting.

Read more >>


November 2019

Nathan White joins PRMA Consulting

PRMA Consulting, is pleased to announce the appointment of Nathan White as Senior Director.

Read more >>


November 2019

Mapping patient involvement in NICE appraisals of oncology products

This study sought to understand the extent of patient involvement in oncology single technology appraisals by NICE, and the key issues that patients focus on.

Read more >>


November 2019

Vote for the PRMA Navigator® in the 2019 Health Economics Innovation Webinar Series

We are proud to announce that the PRMA Navigator® digital application has been shortlisted for the 2019 Health Economics Innovation Series: big ideas accelerating change in HEOR, RWE, and health technology. We hope that you will join the webinar presentation on 11 December and vote for the PRMA Navigator®.

Read more >>


November 2019

Do market access withdrawals impact patient access to treatment in Germany?

In this new market access study, Anja Pownell explores the impact of G-BA resolutions and subsequent market withdrawals on access to treatments for patients.

Read more >>


November 2019

Orphan drug re-assessments in Germany: the impact on additional benefit and price

In her latest market access study, Anja Pownell explores the challenges that orphan drugs face in Germany, specifically when they rapidly reach the re-assessment threshold, and looks at the impact on additional benefit and price.

Read more >>


November 2019

Vicky O'Connor moves to PRMA Consulting

How Vicky O’Connor, new Senior Director at PRMA Consulting, will be supporting clients by linking market access strategy to policy and communications, to ensure a holistic approach.

Read more >>


October 2019

Do your global value dossiers contain these 5 common omissions?

Up to 30% of global health technology assessment template requirements may not be met by your global value dossier. Claire Chadwick explores how you can better support your affiliates by creating a high-quality global value dossier that avoids 5 common omissions.

Read more >>


October 2019

Driving real-time payer insight

Gain competitive advantage with the PRMA Access Accelerator® virtual advisory boards, forums, and online surveys that fast forward your market access strategy.

Learn more >>


October 2019

Transforming value and access outcomes in the Asia-Pacific region

A leading pharmaceutical manufacturer adopted digital technology to transform processes and drive optimal market access for their products. This study summarizes the key challenges, the solutions, and the value gained by the manufacturer.

Read more >>


October 2019

Digitalizing your market access processes will leave you wondering how you managed the “old way” for so long

ISPOR Europe 2019 provides a perfect opportunity to examine the digital transformation of your market access process.

Learn more >>


September 2019

Free eBook: how to accelerate the generation of simultaneous, high-quality HTA submissions

Leading pharmaceutical companies are using the PRMA Navigator® to produce auto-populated draft submissions in as little as 2 weeks. This free eBook explains how the digital application improves the quality of multiple health technology assessment submissions and shortens the time to market access.

Read more >>


September 2019

Overcoming the market access challenges associated with high-cost combination therapies

The scale and potential impact of high-cost combinations coming to market in the next 2–3 years will force a significant change in pricing and reimbursement policies. Steve Fountain evaluates some of market access challenges for pharmaceutical manufacturers using insights gained from the PRMA Innovative Pricing Panel.

Read more >>


September 2019

Championing digital transformation within biotech and pharma companies

Sarah Forrest, Client Excellence Manager at PRMA Consulting, describes how her customer focus and agility enables biopharma clients to feel like they are winning in a digital world.

Read more >>


August 2019

Accelerate the time to patient access with the PRMA Navigator®

This WebEx explains how the PRMA Navigator®, a breakthrough health technology assessment digital application, can help you to accelerate the generation of high-quality HTA submissions enabling patients faster access to new therapies.

Learn more >>


August 2019

Pricing and reimbursement in Canada: a market access update

As the Canadian government announces long-awaited drug pricing reforms, we summarize the healthcare market access news from recent months.

Read more >>


August 2019

The relevance of patient perspectives to value

In the first of a two-part series, we examine the benefits of patient-centric approaches within market access.

Learn more >>


August 2019

Three potential market access strategies for demonstrating value for combination therapies

European advisors met with PRMA Consulting to provide unique, targeted market access insights into the challenges of pricing combination therapies, and to discuss effective strategies for market access success.

Read now >>


August 2019

The influence of the patient voice in regulatory and Health Technology Assessment activities

In the second of a two-part series, we explore how manufacturers and patient advocacy groups can work in partnership.

Learn more >>


July 2019

Improving pharmaceutical portfolio management and decision-making for early assets.

Learn how this top-10 company refined its portfolio management strategy for pre-clinical assets. Capitalizing on the latest digital technology in the pharmaceutical industry, it successfully restructured market access frameworks and prioritized investment decisions.

Read more >>


June 2019

Incorporating the patient voice in market access

There is a growing appreciation of the patient voice in product development and health technology assessment. This article recommends ways to engage with patients during product development and use patient-centric insights more effectively to articulate product value.

Read more >>


June 2019

Pricing and reimbursement of CAR‐T in Germany

CAR-T represents an entirely new way of delivering cancer therapy, with significant challenges for manufacturers and healthcare systems. This study provides an overview of pricing and reimbursement in Germany and offers strategies for success that manufacturers could consider.

Read more >>


June 2019

Improve Health Technology Assessment submissions

This top-5 global pharma company improved the quality of multiple HTA submissions and shortened the time to market access.

Learn how >>


June 2019

Demonstrating value using a new approach to economic modeling

A top-20 pharmaceutical company quickly identified an opportunity to engage with Health Technology Assessment agencies in their exploration of approaches to cost-effectiveness modeling.

Learn how >>


June 2019

Managed entry agreements: theory and principals

Managed entry agreements for pharmaceuticals, biotechnologies, and devices have attracted considerable interest in recent years. This eBook illustrates some of the concepts, and provides an overview of the key principals of engagement that manufacturers could consider.

Read now >>


May 2019

Measuring survival benefit in oncology health technology assessments

Giles Monnickendam examines the scope for health technology assessment agencies to adapt and improve their existing evaluation methods for new oncology treatments.

Read now >>


May 2019

Find out what’s new in CAR-T pricing and reimbursement at EHA 2019

CAR-T represents an entirely new way of delivering cancer therapy. Meet our expert team at EHA 2019 to discuss the challenges for manufacturers and healthcare systems.

Learn more >>


May 2019

Top-5 pharma discovers a new way to evaluate pricing opportunities

This top-5 pharmaceutical company obtained valuable insight when using the PRMA Healthcheck® late module to critically evaluate likely value assessments and pricing opportunities for an asset in different scenarios.

Learn more >>


May 2019

Discover how digital applications are disrupting the market access landscape at ASCO 2019

Evaluate how digital technology can better enable processes and requirements. Meet our senior team at ASCO 2019, or read this article.

Learn more >>


Cloud_computing_benefits
May 2019

Exploring the benefits of cloud computing for market access.

Discover how cloud technology can better enable processes to unlock product value and elevate competitiveness.

Read more >>


10_questions_to_ask_your_suppliers
May 2019

Protecting your market access data. 10 questions to ask your suppliers

To avoid business risks, it is essential to understand your market access data is managed. These 10 frequently asked questions are a good place to start.

Read more >>


May 2019

Identifying critical risks for payer decision-making

Seeking a deeper understanding of risks with their current data package, this top-5 pharmaceutical organization was better equipped to evaluate evidence generation options using analysis from the PRMA Healthcheck® late module.

Discover how >>


Cloud_computing_benefits
May 2019

Protect your market access data: the value of ISO27001

Pharmaceutical and biotechnology manufacturers are increasingly using new technology to collect, analyze, and manage data to solve value challenges and gain strategic advantage. In this market access update, Darren McBride summarizes the importance of reviewing your supplier’s information security standards.

Read more >>


Four_recommendations_to_kick-start
May 2019

Four recommendations to kick-start the digital transformation of your market access processes

TNew technology is disrupting market access processes; embracing its challenges and opportunities is one vital way to drive your business forward. Here are four recommendations for those who are keen to drive change.

Read more >>


May 2019

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Gain insight from payer and pricing experts from across the EU into the reimbursement mechanisms for combination products and the access challenges these mechanisms present for new innovative combinations.

Read more >>


May 2019

EUnetHTA Joint Clinical Assessments: where have we come from and where are we going?

This webinar will explain the evolution of EUnetHTA and its influence to date on EU market access, and outline the scenarios for the future development of this initiative. We will analyze the important differences between assessments by EUnetHTA and those by national HTA agencies, and consider the potential implications for manufacturers of harmonizing HTA approaches to clinical assessment.

Learn how >>


Why Japan’s new cost-effectiveness assessment scheme is “only a starting point” >>

May 2019

Bolstering payer discussions to solve persistent challenges

To accelerate organizational action for a new biomarker strategy, this top-10 pharmaceutical organization addressed challenges, re-invigorated clinical community engagement, and bolstered payer discussions using insight from the PRMA Healthcheck® late module.

Learn how >>


Apr 2019

Managed entry agreements: regional and national insight

This study illustrates the use of managed entry agreements across France, Germany, Italy, Spain, and the UK, and what manufacturers can learn from these agreements.

Read now >>


Apr 2019

Accelerate your market access with technology-enabled consulting

Meet us at ISPOR New Orleans, where we are showcasing the suite of PRMA digital applications. Our evening drinks receptions provide the perfect opportunity to discover how you can make savings, realize your market access vision, and improve your commercial competitiveness.

Meet us at ISPOR New Orleans >>


Apr 2019

Five strategies for CAR-T pricing and reimbursement success

CAR-T therapy currently poses significant challenges for manufacturers and healthcare systems. This overview of pricing and reimbursement strategies provides recommendations for success

Read more >>


Apr 2019

Join our team

We are recruiting: Medical Writer, Market Access Consultant, Senior Analyst, HTA Submissions Manager, HR Business Partner, Consulting PowerPoint Specialist. If you would like the opportunity to work in a cutting-edge market access consultancy and you share our values of quality, collaboration, and creativity, we’d love to hear from you.

Find out more about a career with us >>


Apr 2019

Drive readiness for payer submissions for your Phase 2 and 3 products

Five new case studies describe how leading manufactures have transformed their market access processes with the PRMA Healthcheck® late module.

Learn how >>


Apr 2019

Recommendations for successfully developing managed entry agreements

Even with tough environmental challenges and a powerful negotiating body, agreements can be reached. Read these key points for successfully developing MEAs that work for all parties.

Read more >>


Apr 2019

Designing effective managed entry agreements: insight from Spain

A recent meeting of complex pricing experts suggested these approaches to be successful and replicable.

Read more >>


Mar 2019

Accelerate the generation of high-quality, simultaneous draft HTA submissions

The PRMA Navigator® now eliminates the prolonged searching and transferring of content from global, regional and local supporting materials to draft HTA submissions.

Read more >>


Mar 2019

Patient centricity: a crucial approach for market access?

As the focus of healthcare providers shifts to placing patients at the center of their activities, it is important for pharmaceutical and biotechnology industries to adopt more patient-centric ways of working. Gain recommendations for enhancing your patient-centric market access strategy with this free eBook

Read now >>


Feb 2019

Future proofing for the 2020s: market access trends

This webinar discusses the emerging trends in market access and anticipates how successful manufacturers will prepare for competitively advantageous product launches in the early 2020s.

Learn more >>


Feb 2019

Biosimilars: market access considerations

As the biosimilar market expands, payers are looking to take advantage of potential budget savings. This free eBook summarizes the benefits and challenges for biosimilars, and points for differentiating your product from competitor biosimilars and/or the reference product.

Read now >>


Feb 2019

Your data security is at the heart of our business

We are proud to have been awarded ISO27001 certification, a global standard that recognizes our commitment to cloud security, safeguarded information management, and the protection of your business data.

Read more >>


Feb 2019

Potential solutions for pricing and reimbursement of high-cost combination products

The PRMA Consulting Expert Advisory Group on Complex Pricing recently discussed pricing and reimbursement of high-cost combination products, with a particular focus on oncology therapies.

Drawing on their legal and policy expertise from across the EU, the cross-functional advisors explored the current reimbursement mechanisms for combination products, challenges these present for access for new innovative combinations, the scope for potential solutions, and the current policy direction on this within France, Germany, and the UK. Contact us for a confidential discussion about the findings.

Get in touch >>


Feb 2019

First CAR-T assessment issued by CADTH

Read the key findings.

Read now >>


Feb 2019

How are digital applications transforming the value and access functions?

Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and are increasingly using digital technology to optimize market access for their products. We believe that there are three key benefits for market access.

Read more >>


Jan 2019

Explore early evidence planning solutions at DIA Europe 2019

Discover how we can help you develop an integrated early evidence strategy that anticipates and navigates the complex market access requirements from pre-clinical development and beyond.

Meet us at DIA Europe >>


Jan 2019

Discover solutions to pricing challenges for high-cost combinations

If you are facing complex pricing challenges, a good place to test your strategies and solutions is the PRMA Expert Advisory Group. This unique global community of experienced, multi-disciplinary experts has proudly gained an international reputation for improving the complex pricing strategies of leading pharmaceutical and biotechnology companies.

Ask your question >>


Jan 2019

Reinvigorate your market access with the PRMA Navigator® 

Now is the perfect time to discover how to accelerate time to market, while delivering greater quality and savings. Test-drive the latest version of our cutting-edge digital application.

Read more >>


Jan 2019

Drive payer submission readiness for your Phase 2 and 3 products

With a systematic assessment of payer evidence readiness for your product against actual submission template requirements, the PRMA Healthcheck® late module advances your organizational vision and action plan to optimize payer readiness.

Discover how >>


Dec 2018

Evaluate how digital technology can better enable processes and requirements

Harnessing digital applications to explore value options, gain strategic advantage and provide innovative market access solutions.

Read more >>


Nov 2018

PRMA Consulting presents award winning research at ISPOR Europe

We are incredibly proud of our team who have received the award for Best General Poster Research Presentation at ISPOR Europe 2018.

This recognizes the scientific merit of their work, “Impact of European Medicines Agency Clinical Trial Transparency Policies on Health Technology Assessment Decisions in Germany”.

Learn more >>


Nov 2018

Accelerate the generation of simultaneous HTA submissions

Gain a head start on your HTA submissions with auto-population, delivering up to 80% of a draft submission and maximizing the use of supporting materials.

Learn more >>


Nov 2018

Join us at the 60th ASH Annual Meeting

Find out how new developments in CAR-T pricing and reimbursement can help you reach your market access goals.

Meet with us at ASH >>


Nov 2018

Managed entry agreements lessons from EU5

Gain an insight into different approaches to managed entry agreements at national, regional, and local level by watching this webinar. Understand the practical implications for manufacturers, payers, and healthcare systems, and identify the considerations for the design of effective managed entry agreements

Learn more >>


Nov 2018

Meet with us at ISPOR Europe

Utilized by Market Access and HEOR professionals from affiliate to global level, the cutting edge PRMA digital applications unlock and optimize value from early product development through to successful HTA submissions. ISPOR Europe provides the perfect opportunity to experience the intuitive functionality of the secure and scalable applications.

Meet with us at ISPOR Europe >>


Oct 2018

Translate advances in oncology and gene therapy into successful market access strategy

Join our international senior team at ESMO 2018 to discuss your specific business challenges, examine global CAR-T insight from complex pricing experts and test-drive the latest, transformative digital applications.

Meet with us at ESMO >>


Oct 2018

CAR-T therapy: the future begins to take shape

What can HEOR and market access teams learn from CAR-Ts’ early pricing and reimbursement experience and health-system implementation plans? The current status and key issues for pricing and reimbursement of CAR-T therapy in the US, UK, France, and Germany are examined in this presentation. You will gain insight into the practical implications for health technology assessment, patient access, and the development of funding and delivery models within public healthcare systems for these breakthrough therapies.

Learn more >>


Oct 2018

Leading pharma launches new immunotherapy using insight from the PRMA Tracker®

To support the successful launch of a new immunotherapy for a fast-evolving indication, this noted pharmaceutical company required an in-depth understanding of the latest payer thinking across rapidly advancing global markets. Find out how they approached the challenge.

Read now >>


Sep 2018

Maximize the pricing and market access potential of your early pipeline

A top-10 pharmaceutical company sought to make informed decisions for an early pipeline product, with little data available. Find out how they established a consistent approach to comparative assessment of market access risks and opportunities to guide their early decision-making.

Read now >>


Sep 2018

Pricing and reimbursement insights for Gene Therapies

A recent meeting of complex pricing experts focused on the challenges and solutions for pricing and reimbursement in the area of innovative cell and gene therapy products. The bespoke group shared knowledge from a range of countries and different roles within healthcare systems, to bring a practical and pragmatic approach to issues related to pricing. We are pleased to share our highlights from this thought-leading meeting.

Read more >>


Sep 2018

Yescarta and Kymriah cell therapy: key areas to watch

With NICE’s rejection of Gilead’s Yescarta for treating DLBCL and NHS England’s announcement that a deal has been agreed with Novartis to fund Kymriah for childhood ALL, what are the implications for CAR-T manufacturers and assessment agencies?

Read more >>


Aug 2018

Achieving a variable price by indication: free eBook download

For manufacturers seeking to optimize the value of assets in development across multiple indications, there are alternative options to achieve a variable price by indication, other than the classic method of indication-specific rebates. Our free eBook helps you understand the variance in schemes and provides insight for selecting the most appropriate scheme.

Read now >>


Aug 2018

Over 40 readiness assessments successfully delivered by the PRMA Healthcheck® late module

PRMA Consulting is celebrating the successful support of over 40 readiness assessments using its digital application, the PRMA Healthcheck® late module. Created to drive payer submission readiness for Phase 2 and 3 products, the application is the result of 5 years’ collaboration with leading pharmaceutical companies to meet their market access challenges.

Read now >>


Aug 2018

Indication-based pricing: your free eBook download

Challenges for the commercialization of products that offer different value in different indications may be overcome with indication-based pricing strategies. This free eBook offers you insights into the key concepts and suggests ways to develop a value proposition.

Read now >>


Aug 2018

A smarter way to inform product strategy and planning dialogue

With the new version release of the PRMA Healthcheck® late module, you can inform high level conversations regarding product strategy and planning with an easily digestible synopsis of key vulnerabilities and proposed evidence generation projects. This is just one new way that our intuitive application helps you drive payer submission readiness for your Phase 2 and 3 products.

Read now >>


Jul 2018

Achieve up to 80% auto-population of your first draft HTA submission

A top-5 global pharma company investigated digital solutions from various companies to improve the quality and development timelines of simultaneous HTA submissions. The global team and affiliate countries selected the PRMA Navigator® application to auto-populate a partial submission for each country within 2 weeks.

Read now >>


Jul 2018

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma

Treatment decisions for advanced melanoma are increasingly complex as the landscape quickly evolves. This European expert panel study sought to understand which patient characteristics and disease-related factors inform clinicians' choices of first-line treatment for BRAF-mutated melanoma.

Read now >>


Jun 2018

Demonstrating product value through the revised ESMO value framework

This case study outlines the approach taken when a client sought to understand how changes to the ESMO-MCBS would affect the perceived value of their products and how these perceptions aligned with HTA outcomes.

Read now >>


May 2018

Experience our new digital applications

We warmly invite you to our drinks reception and demonstration of new digital applications at the ISPOR Global Conference in Baltimore, from 6pm on Monday 21 May and Tuesday 22 May on booth 807. This is the ideal opportunity to experience our latest solutions and discuss your specific market access challenges with members of our senior leadership team.

Meet with us at ISPOR Baltimore >>


May 2018

What role does the patient perspective play in determining access to innovative therapies?

Join us at ASCO 2018 to discover more about the differences between the EU and US perspectives on HRQL.

Meet with us at ASCO >>


May 2018

Indication-specific pricing: the obvious solution?

This presentation examines the opportunities and challenges for manufacturers and payers in implementing indication-based pricing strategies. You will gain an understanding of the complexities that multiple indication and combination products present for pricing and reimbursement and obtain actionable insights for developing a value proposition for indication-specific pricing.

Learn more >>


Apr 2018

Leveraging the value frameworks scoring of a new treatment and comparators

See the approach taken when a client sought to understand how various value frameworks would score their new treatment, in comparison to competitor products, and how this could be leveraged in the value proposition.

Read now >>


Apr 2018

Tailored solutions for early planning in market access

Visit booth 29 at DIA Europe and discover how we can help you develop an integrated early evidence strategy that anticipates and navigates complex market access requirements from pre-clinical development and beyond.

Meet with us at DIA Europe


Mar 2018

Value and Access: striking a balance
Join us in an expert discussion at DIA Europe

Ensuring optimal access at appropriate value is a balancing act. Our senior director, Jan McKendrick, is pleased to be participating in a thought leading discussion at DIA Europe which will address key questions on the topic taking into account multiple perspective. As part of the session, Jan will present international evidence of the impact of reimbursement and licensing discrepancies on patient access before a discussion on harmonisation and the path forward.

Visit booth 29 to discuss this with Jan in more detail.

Meet with us at DIA Europe


Mar 2018

3 reasons why an expert advisory group can help with your complex pricing challenges

Manufacturers seeking to execute complex pricing schemes rapidly and effectively need to approach payers with well-developed solutions, adapted to a range of country requirements and aligned with the changing landscape. Find out how an expert advisory group can help you with your complex pricing issues

Read now >>


Mar 2018

Payer perspectives on cell and gene therapies: 9 key challenges

Assessing payer perspectives on the rapid developments in regenerative medicines and cell therapy, we highlight the key challenges and opportunities for the clinical pipeline.

Read now >>


Feb 2018

CAR-Ts therapy and indication-specific pricing in Europe: new insights

A recent meeting of complex pricing experts from across the EU5 countries focused on the variability among countries of payers’ and policy-makers’ attitudes to innovative pricing, and the practical challenges for implementation of complex pricing schemes capable of satisfying a range of country requirements and accommodating the rapidly evolving landscape. We are pleased to share our highlights from this thought-leading meeting.


Feb 2018

Running the half-marathon for Addison's Disease Self-Help Group

A team of colleagues from PRMA Consulting are challenging themselves by running the Fleet half-marathon in March; for one of the group this will be a training run for the Rotterdam marathon a few weeks later!

Through our running, we would like to raise awareness and much needed funds for the Addison's Disease Self-Help Group. We recently became aware of the impact of this disease on a young child and his family; thankfully he survived and is learning to live with his condition.

Thank you for taking the time to visit our JustGiving page.


Dec 2017

Launch of the expert advisory group on complex pricing

The PRMA Consulting team are excited to launch the inaugural meeting of our expert advisory group focused on complex pricing. The group will look at recent and emerging US experience with CAR-Ts and evaluate potential pricing models in the EU. We will also discuss the challenges and opportunities to indication-specific pricing in Europe. We will share highlights from this meeting with clients after the holidays.

Contact us to find out more about our advisory groups.


Dec 2017

CAR-Ts: access challenges and opportunities

Following our successful webinar yesterday on ‘Market access considerations for CAR-Ts: insights from ASH’, please find more information about how we can help you with your access challenges and opportunities for CAR-Ts.


Oct 2017

Our Senior Director, Jan McKendrick, discusses the impact of discrepancies between licensing and country-specific reimbursement decisions on patient access to cancer treatment


Jan 2018

Payer perspectives on cell and gene therapies: opportunities and challenges

This new webinar has true cross-functional value for everyone working in market access in the pharmaceutical industry. From non-expert audiences through to subject-matter experts. Professor Stephen Palmer from the University of York will join us to discuss his recent work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.


Nov 2017

Patient-centricity: shaping value generation for HTA and market access

With patient-centricity becoming a new paradigm for the pharmaceutical industry, this webinar will examine the role of patient engagement in HTA and market access processes, and how this enhances value generation for drug approvals. Focusing on Europe, we will analyze the different models and guidelines in place.


"Please let your staff who supported us know how appreciative we are of their efforts. From the advisory boards to the GVD development to the modeling efforts and numerous projects, the support and partnership was great. The accomplishment in the UK with NICE is absolutely exceptional."

Therapeutic Area Head, GHE Oncology Therapeutics, at a top-20 pharmaceutical company
Nov 2017

ISPOR Glasgow is nearly upon us! Join us at booth 404 to discuss your market access challenges


Jun 2017

Market access update key learnings from ASCO and EHA 2017

In this webinar, we discuss the evolution of value frameworks, the OCM, and incorporating the patient perspective. We also consider the implications for payers of new data on CAR-Ts; key points to think about when planning for market access of a combination; and how payers might handle products approved on the basis of basket trials.


"Just wanted to say great job presenting today. The commercial team increasingly want to be involved in these discussions and your discussion points and delivery were great for the access and broader team. Thanks for making the information practical and insightful. I think the overall response from the team was very positive and the content will ultimately be incredibly helpful for our strategy."

Senior Manager, Oncology Global Market Access and Pricing, at a top-20 pharmaceutical company
Mar 2017

Market access for PD-1 inhibitors: where are we now?

With three products targeting the PD-1 pathway now approved, and other launches expected in 2017, this webinar will take stock of payers’ reactions to the products. Focusing on Europe, we will look at the decisions that have been made to date and discuss these further.


info@prmaconsulting.com
UK (HQ) +44 (0)1252 786284
US +1 (415) 655 6798

Company registration number: 05893400

Follow us


Terms and conditions
Privacy statement
Cookie policy